A5025370928- Liver Disease Diagnosis and Treatment
- Liver Disease and Transplantation
- Hepatitis C virus research
- Hepatitis B Virus Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Nutrition and Health in Aging
- Alcohol Consumption and Health Effects
- Diet, Metabolism, and Disease
- Artificial Intelligence in Healthcare
- Metabolism, Diabetes, and Cancer
- Cholangiocarcinoma and Gallbladder Cancer Studies
- COVID-19 Clinical Research Studies
- Cancer Immunotherapy and Biomarkers
- Diabetes Management and Education
- Amoebic Infections and Treatments
- Lymphatic System and Diseases
- Diet and metabolism studies
- Cardiovascular Disease and Adiposity
- Helicobacter pylori-related gastroenterology studies
- Gastroesophageal reflux and treatments
- HIV-related health complications and treatments
- Body Composition Measurement Techniques
- Chemotherapy-induced cardiotoxicity and mitigation
- Veterinary medicine and infectious diseases
- Diagnosis and Treatment of Venous Diseases
Ewha Womans University
2021-2025
Ewha Womans University Medical Center
2021-2025
Yonsei University
2020-2023
Catholic University of Korea
2023
Severance Hospital
2020-2021
Sarcopenia is a significant indicator of the severity non-alcoholic fatty liver disease. We investigated whether sarcopenia could identify subgroups with different risk fibrosis and atherosclerotic cardiovascular disease (ASCVD) among subjects metabolic dysfunction-associated (MAFLD).Subjects from Korea National Health Nutrition Examination Survey 2008-2011 were selected (n = 8361). was defined using index. Hepatic steatosis as index ≥30. Significant fibrosis-4 (FIB-4) ≥2.67 or highest...
Abstract Background and Aims Cardiovascular disease (CVD) is the main cause of mortality in subjects with non‐alcoholic fatty liver (NAFLD). We investigated association between CVD risk metabolic dysfunction‐associated (MAFLD) or NAFLD influence significant fibrosis on risk. Methods Subjects who underwent a comprehensive medical check‐up were recruited (2014–2019). Significant was defined using score, fibrosis‐4 index, aspartate aminotransferase to platelet ratio FibroScan‐aspartate score....
Background/Aims: Metabolic dysfunction-associated fatty liver disease (MAFLD) is categorized into three subtypes: overweight/obese (OW), lean/normal weight with metabolic abnormalities, and diabetes mellitus (DM).We investigated whether fibrotic burden in differs across subtypes of MAFLD patients. Methods:This cross-sectional multicenter study was done cohorts subjects who underwent a comprehensive medical health checkup between January 2014 December 2020.A total 42,651 patients...
Clinical features of non-alcoholic fatty liver disease (NAFLD), but not fulfilling the diagnostic criteria metabolic dysfunction-associated (MAFLD), remain unclear. We investigated risk sarcopenia and cardiovascular (CVD) in MAFLD non-metabolic (MR) NAFLD. Subjects were selected from Korean National Health Nutrition Examination Surveys 2008-2011. Liver steatosis was assessed using index. Significant fibrosis defined fibrosis-4 index, categorized by age cut-offs. Sarcopenia as lowest quintile...
Cardiovascular disease (CVD) is the principal cause of death in patients with type 2 diabetes (T2D). In this study, we assessed whether liver fibrosis predicted risk CVD T2D.A total 1481 who had commenced oral antidiabetic drugs to treat newly diagnosed T2D between 2006 and 2010 were recruited. The fibrosis-4 index (FIB-4), non-alcoholic fatty score (NFS), BARD used assess fibrotic burden at time diagnosis.During follow-up period (median 88.1 [interquartile range 36.6-113.6] months), 242...
Background and Aims: In the general population, previous studies reported that physical activity was associated with risk of hepatocellular carcinoma (HCC) development. However, it is unclear whether HCC development in patients chronic hepatitis B (CHB). We aimed to elucidate association between CHB patients. Methods: This nationwide cohort study involved treatment-naive (n = 9727) who started treatment entecavir or tenofovir answered self-reported questionnaires January 2012 December 2017,...
Transarterial radioembolization (TARE) has become widely used in the treatment of HCC, one most common causes cancer mortality worldwide. Here we investigated long-term clinical outcomes patients with hepatocellular carcinoma (HCC) treated TARE a multi-medical center Korea. A total 149 from 2008–2014 were recruited. The pre-treatment HCC stage was classified according to BCLC stage, which C and D defined as advanced HCC. Advanced Child–Turcotte–Pugh (CTP) score identified 62 (42%) 134 (90%)...
Trans-arterial radioembolization (TARE) is a form of radiation therapy performed for hepatocellular carcinoma (HCC) via selective intra-arterial injection Yttrium-90-loaded microspheres. This was multi-center retrospective study consecutive patients with HCC who underwent TARE between July 2009 and May 2019. Using pre-treatment computed tomography imaging, the total cross-sectional area (cm2) abdominal skeletal muscle at third lumbar vertebra measured. The index (SMI) calculated by...
Trans-arterial radioembolization (TARE) is a form of radiation therapy performed for hepatocellular carcinoma (HCC) via selective intra-arterial injection Yttrium-90 loaded microspheres. This was multicenter retrospective study consecutive patients with HCC who underwent TARE between July 2009 and May 2019. Using pre-treatment computed tomography imaging, the total cross-sectional area (cm2) abdominal skeletal muscle at third lumbar vertebra measured. The index (SMI) calculated by...
Backgrounds: It is unclear which patients benefit from resection in intermediate-stage-hepatocellular carcinoma (HCC). The authors aimed to identify high-risk for early recurrence among with resectable intermediate-stage HCC. Methods: This multicenter retrospective study included who underwent or trans-arterial chemoembolization (TACE) HCC (2008–2019). Multivariable Cox proportional analysis was performed when treated resection. A prediction score 2-year recurrence-free survival (RFS)...
Abstract Aim Risk prediction models for hepatocellular carcinoma (HCC) development are available. However, the influence of antiviral therapy (AVT) on these in patients with chronic hepatitis B is unknown. Methods The dynamic changes risk during AVT and association between model B‐related HCC were investigated. Between 2005 2017, 4917 (3361 noncirrhotic, 1556 cirrhotic) recruited. Results mean age study population was 49.3 years 60.6% ( n = 2980) male. Chinese University‐HCC (CU‐HCC) score...
Hepatocellular carcinoma (HCC) primarily originates in the liver with hepatic differentiation. However, HCCs are not homogenous, and approximately 35% of HCC cases classified as histopathological variants that present distinct pathologic characteristics. In particular, lymphocyte-rich variant is rarest subtype accounting for less than 1% HCCs, which well known to date about molecular features pathophysiology. Herein, we a case patient who was suspected metastatic cancer confirmed...